

Humana, Medicare Rank Well on Payer Measures

BY ALICIA AULT

Associate Editor, Practice Trends

In an assessment of performance by one of the nation's largest physician revenue management companies, Humana and Medicare were rated highest when it came to paying quickly and being easy to work with.

The data were tabulated and made public by AthenaHealth, a company in Woburn, Mass., that manages \$2 billion in revenues for 7,000 physicians, nurses, and other health care providers in 33 states.

In explaining why the company decided to make the data available—free of charge—Jeremy Delinsky, director of process innovation at AthenaHealth, said, “We found the story was too compelling to sit on.” And, physicians who know

Physicians who know more about their insurers will have more leverage in contracting and a better opportunity to improve their bottom line.

more about their insurers will have more leverage in contracting and a better opportunity to improve their bottom line, he said.

The company assessed 5 million “charge lines” worth of claims data from the fourth quarter of

2005. To be a part of the ranking, national payers had to have at least 10,000 “charge lines,” or line items, and regional payers at least 3,000.

Insurers were ranked according to an overall index that gave the most weight to financial performance. That performance included the number of days in accounts receivable, the percentage of claims paid and closed on the first pass, and the percentage of charges transferred to the patient. The index also included an administrative measure encompassing the claims denial rate, the percentage requiring a phone call to clarify a response from the insurer, and the percentage of claims lost. Finally, a small amount of weight was given to the difficulty of working within the payer's rules.

Nationally, Humana ranked number one, followed by Medicare, United Health Group, Aetna, Cigna, Champus, and Wellpoint. According to AthenaHealth, Aetna denies claims twice as often as Humana, and the reasons are so unclear that 17% of claims need follow-up calls. Wellpoint tended to take the longest to pay and was the most aggressive in shifting responsibility to physicians to get payments from patients.

For all payers, claims stay in accounts receivable for an average of 38 days.

There was considerable variation in performance at the regional level. In the northeast, for example, BlueCross BlueShield of Pennsylvania/ Independence BlueCross was the top-ranked plan, followed by Tufts Health Plan. In the west, PacifiCare was first, followed by Medicare B in Texas and United Health Group. The largest regional payers mostly provided clear reasons for denials, rarely shifted the responsibility to physicians to secure pay-

ment, and paid most claims on first submission and within 30 days.

Regional payers seemed to be more efficient and perhaps even more powerful than the national insurers, said Mr. Delinsky. National payers have been growing in size, but “it's unclear whether consolidation has resulted in the scale they hoped for.”

AthenaHealth did not assess payers' relative reimbursement rates because it would not be legal to publicize those rates, Mr. Delinsky said. However, he suggested

that physicians could use his company's rankings to negotiate for a higher fee if the payer is hard to work with, or potentially accept a lower payment rate if the insurer pays more quickly and imposes less of an administrative burden.

The insurance industry did not respond directly to the rankings, but America's Health Insurance Plans, a national trade association, recently completed a study showing that 98% of claims submitted electronically are processed within a

month of receipt. The study, based on aggregated data from 25 million claims processed by a sample of 26 health insurers, found that 75% of claims are submitted electronically, up from 24% in 1995.

If there is a delay in payment, it's often because the claim has not been received in a timely manner from the physician's office, according to AHIP. ■

Go to www.athenapayerview.com to view the full rankings.

Give your patients the simplicity of **one**

One insulin. Two actions.

One simple way to help control diabetes.

NovoLog® Mix 70/30 is...

- **Simply dosed**—easy once- or twice-daily starter therapy^{1,2}
- **Effective**—once- and twice-daily dosing gets up to 70% of patients to ADA goal^{2*}
- **Safe**—low rate of hypoglycemia^{3,4}
- **Complete**—fasting (FPG) and postprandial (PPG) coverage^{1,5}
- **The patient-preferred pen**¹—NovoLog® Mix 70/30 FlexPen^{®6}
- **Covered**—on most managed care formularies

Satisfaction Guarantee⁴ to help patients progress toward glycemic goals.

^{*}ADA goal is A1C <7%.

¹74% of patients preferred NovoLog® Mix 70/30 FlexPen[®] versus 9% who preferred insulin lispro mix 75/25 prefilled pen for overall ease of use. 17% of respondents had no preference.

²Subject to program details included in the Satisfaction Guarantee Patient Folio.



novo nordisk®

NovoLog® Mix 70/30

70% insulin aspart protamine suspension and 30% insulin aspart injection, (rDNA origin)

Give your patients the simplicity of **one**

Important Safety Information: Because NovoLog Mix 70/30 has peak pharmacodynamic activity 1 hour after injection, it should be administered with meals. Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, species, or method of manufacture may result in the need for a change in dosage. NovoLog Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog Mix 70/30 or one of its excipients. Because of differences in the action of NovoLog Mix 70/30 and other insulins, care should be taken in patients in whom these conditions may be clinically relevant (eg, patients who are fasting, have autonomic neuropathy, are using potassium-lowering drugs, or are taking drugs sensitive to serum potassium level). Do not mix NovoLog Mix 70/30 with any other insulin product.

The significance, with respect to the long-term clinical sequelae of diabetes, of the differences in postprandial hyperglycemia between treatment groups has not been established.

Indications and Usage: NovoLog Mix 70/30 is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia.

Please see brief summary of Prescribing Information on adjacent page. FlexPen and NovoLog are registered trademarks of Novo Nordisk A/S. © 2006 Novo Nordisk Inc. 129960R March 2006